Endocrinology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

3. Rapid correction of low vitamin D status in nursing home residents

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Medicare pay-for-reporting effort draws fire from frustrated doctors

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Survival of patients with metastatic malignant pheochromocytoma and efficacy of combined cyclophosphamide, vincristine and dacarbazine chemotherapy
Journal of Clinical Endocrinology and Metabolism, 06/09/09

Nomura K et al. - In a study to analyze survival curves and survival times of pts with malignant pheochromocytoma and determine the efficacy of chemotherapy on prolongation of life, this study revealed a long survival time. Vincristine and dacarbazine (CVD) chemotherapy was not shown to extend survival, especially for women and pts with adrenal gland-derived primary tumors.

Methods

This was an inception cohort and Kaplan-Meier survival analysis.
32 pts with metastasized malignant pheochromocytoma were analyzed for survival.
25 pts had undergone excision of their primary tumors.
Survival curves were compared among 16 pts in the group treated with combined chemotherapy using CVD and 9 pts not treated with chemotherapy.

Results

The survival curve of the 32 pts declined continuously and linearly to at least 20 yrs after diagnosis of pheochromocytoma.
The 50% survival rate was estimated to be 14.7 yrs.
In the 25 pts whose primary tumor was excised, pts who already had metastases at the time of pheochromocytoma diagnosis had better survival than those whose metastases were found later.
Survival rate after diagnosis of metastasis was worse in the CVD group than in controls.
When the effects of CVD were examined after stratifying several factors, female gender and adrenal origin of tumor were found to be negative prognostic factors for CVD chemotherapy.

<< Previous
Clinical Experience with Continuous Glucose Monitoring in Adults

Next >>
Rosiglitazone evaluated for cardiovascular outcomes in oral agent...